Misonix BoneScalpel(TM) Highlighted In New Clinical Paper Aimed At Face And Jaw
Surgery
FARMINGDALE, N.Y., March 5, 2013 /PRNewswire via COMTEX/ -- Misonix, Inc.
(nasdaqgm:MSON), an international surgical device company that designs,
manufactures and markets innovative therapeutic ultrasonic products for spine
surgery, skull-based surgery, neurosurgery, wound debridement, cosmetic surgery,
laparoscopic surgery and other surgical applications, announces a new clinical
paper accepted for publication by "The International Journal of Oral &
Maxillofacial Surgery," a well-respected, peer-reviewed journal. Entitled
"Ultrasonic Orthognathic Surgery; Enhancements to Established Osteotomies,"
authored by Gilles, Couvreur and Dammous, from the Department of Oral and
Maxillofacial Surgery, Clinique de Esperance, Montegnee, Belgium, the clinical
paper is circulated to leading oral, maxillofacial and reconstructive surgeons.
Orthognathic surgery refers to the correction of abnormal conditions affecting
the jaw or face; osteotomies refer to the bone dissection (cutting) necessary to
reposition bone during these surgeries. Given the attributes of the Misonix
BoneScalpel, as described below, the use of traditional power instruments, such
as saws or burrs, was unnecessary for this study.
It was noted that the Misonix BoneScalpel Ultrasonic Bone Cutter (osteotome)
offers a safe and efficient method to create precise cuts during the transection
of bone during reconstructive surgery of the jaw and face, generally required as
a result of birth defects and other abnormalities. Primary advantages, as
reported, include improved control, a largely bloodless operative field for
improved visualization, precise osteotomies (cuts through bone), significant
reductions in the occurrence of nerve impairment, and significant reductions in
'bad bone splits' that may require additional corrective surgery.
In the words of Dr. Roland Gilles, MD, DDS, one of the clinical investigators;
"We adapted the ultrasonic blade of the BoneScalpel to serve as a universal
instrument for orthognathic and maxillofacial surgery. We have since performed
well over 100 procedures including orthognathic, reconstructive and oncologic
surgeries. Using the BoneScalpel, we have much better control over the osteotomy
and have observed significantly fewer bad splits and reductions in nerve
impairment, swelling, hematoma, operative time and hospital stay."
The Misonix BoneScalpel(TM), which was used to perform the study, is a novel
ultrasonic osteotome (bone cutting device) used for safe, tissue-selective bone
dissection that encourages en-bloc bone removal and refined osteotomies while
sparing elastic soft tissue structures. Most users report that the surgical field
is relatively bloodless and clean. Loss of viable bone is minimal and
controllable. In addition to maxillofacial and reconstructive surgery, the
BoneScalpel has been used extensively for bone removal in the cervical, thoracic
and lumbar spine, including spinal deformity surgery.
"We are proud to report such an impressive clinical experience with the Misonix
BoneScalpel when used in advanced orthognathic surgery," said Michael A. McManus,
Jr., President and Chief Executive Officer of Misonix. "In many procedures in
spine surgery, as well as maxillofacial surgery, we are now seeing that surgeons
are finding less bleeding, as was observed by Dr. Gilles, et al, which
contributes to faster, safer procedures that require less time in the hospital.
It is our privilege to work with world renowned surgeons and to provide state of
the art ultrasonic surgical technology to prestigious institutions throughout the
world."
About Misonix Misonix, Inc. designs, develops, manufactures and markets
therapeutic ultrasonic medical devices. Misonix's therapeutic ultrasonic platform
is the basis for several innovative medical technologies. Addressing a combined
market estimated to be in excess of $3 billion annually; Misonix's proprietary
ultrasonic medical devices are used for wound debridement, cosmetic surgery,
neurosurgery, laparoscopic surgery, and other surgical and medical applications.
Additional information is available on the Company's Web site at
misonix.com.
Safe Harbor Statement With the exception of historical information contained in
this press release, content herein may contain "forward looking statements" that
are made pursuant to the Safe Harbor Provisions of the Private Securities
Litigation Reform Act of 1995. These statements are based on management's current
expectations and are subject to uncertainty and changes in circumstances.
Investors are cautioned that forward-looking statements involve risks and
uncertainties that could cause actual results to differ materially from the
statements made. These factors include general economic conditions, delays and
risks associated with the performance of contracts, risks associated with
international sales and currency fluctuations, uncertainties as a result of
research and development, acceptable results from clinical studies, including
publication of results and patient/procedure data with varying levels of
statistical relevancy, risks involved in introducing and marketing new products,
potential acquisitions, consumer and industry acceptance, litigation and/or court
proceedings, including the timing and monetary requirements of such activities,
the timing of finding strategic partners and implementing such relationships,
regulatory risks including approval of pending and/or contemplated 510(k)
filings, the ability to achieve and maintain profitability in the Company's
business lines, and other factors discussed in the Company's Annual Report on
Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form
8-K. The Company disclaims any obligation to update its forward-looking
relationships.
Investor Relations Contacts
Misonix Contact:Lytham Partners, LLC
Richard ZarembaRobert Blum, Joe Dorame, Joe Diaz
631-694-9555602-889-9700
invest@misonix.com mson@lythampartners.com |
